

# A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts

Ralph J. Abi-Habib, Shihui Liu, Thomas H. Bugge, Stephen H. Leppla, and Arthur E. Frankel

**Novel agents to treat acute myeloid leukemia (AML) are needed with increased efficacy and specificity. We have synthesized a dual-specificity fusion toxin DTU2GMCSF composed of the catalytic and translocation domains of diphtheria toxin (DT) fused to the granulocyte-macrophage colony-stimulating factor (GM-CSF) in which the DT furin cleavage site  $_{163}\text{RVRRSV}_{170}$  is modified to a urokinase plasminogen activator (uPA) cleavage site  $_{163}\text{GSGRSA}_{170}$ , termed U2. DTU2GMCSF was highly toxic to the TF1-**

**vRaf AML cell line (proliferation inhibition assay;  $\text{IC}_{50} = 3.14 \text{ pM}$ ), and this toxicity was greatly inhibited following pretreatment with anti-uPA and anti-GM-CSF antibodies. The activity of this toxin was then tested on a larger group of 13 human AML cell lines; 5 of the 13 cell lines were sensitive to DTU2GMCSF. An additional 5 of the 13 cell lines became sensitive when exogenous pro-uPA was added. Sensitivity to DTU2GMCSF strongly correlated with the expression levels of uPA receptors (uPARs) and GM-CSF receptors (GM-**

**CSFRs) as well as with total uPA levels. DTU2GMCSF was less toxic to normal cells expressing uPAR or GMCSFR alone, that is, human umbilical vein endothelial cells and peripheral macrophages, respectively. These results indicate that DTU2GMCSF may be a selective and potent agent for the treatment of patients with AML. (Blood. 2004;104:2143-2148)**

© 2004 by The American Society of Hematology

## Introduction

Combination induction and consolidation chemotherapy yields complete remissions in a high proportion of patients with acute myeloid leukemia (AML). However, the majority of patients eventually have a relapse due to the persistence of chemotherapy-resistant blasts.<sup>1</sup> Because most chemotherapy drugs cause DNA damage or block cell proliferation, we sought to target refractory AML blasts with agents that use different molecular cytotoxicity mechanisms. One such approach consists of targeting the protein synthesis inhibitor diphtheria toxin (DT) to the AML cells.

DT is composed of a cell-binding domain, a translocation domain, a furin-sensitive loop, and a catalytic domain.<sup>2</sup> Recombinant DT molecules have been prepared by replacing the cell-binding domain of DT with tumor-specific peptide ligands.<sup>3</sup> Our laboratory has focused on the development of recombinant DT molecules for the treatment of AML.

We and others first synthesized DT<sub>388</sub>GMCSF consisting of the catalytic and translocation domains of diphtheria toxin (DT<sub>388</sub>) fused to human granulocyte-macrophage colony-stimulating factor (GM-CSF).<sup>4,5</sup> DT<sub>388</sub>GMCSF was selectively toxic to leukemic blasts in vitro, efficacious in animal models, and active in patients.<sup>6-8</sup> Remissions were observed in 10% of patients, but liver injury secondary to toxicity to normal GM-CSF receptor (GM-CSFR)-expressing cells (eg, liver macrophages) limited dose escalation.

To enhance the specificity of DT<sub>388</sub>GMCSF, we sought to find additional cell surface AML-specific molecules absent from normal tissues expressing GM-CSFR. Liu et al<sup>9</sup> pioneered redirecting toxins by modifying the furin cleavage site in the toxin to a tumor-selective urokinase plasminogen activator (uPA) cleavage sequence. uPA is a serine protease that cleaves plasminogen into its active form, plasmin. uPA is synthesized and released as pro-uPA, a single-chain inactive form, which is then cleaved into the double-chain active uPA by plasmin and other proteases. Active uPA binds to its receptor (uPAR), forming a potent uPA/uPAR extracellular serine protease system. The uPA/uPAR system is overexpressed in a variety of tumors including leukemias.<sup>10,11</sup> AML blasts overexpress uPA and uPAR,<sup>12</sup> whereas most normal tissues have no or little uPA and uPAR expression, except when they are up-regulated during certain physiologic processes such as wound healing and extracellular matrix remodeling.<sup>10,11</sup> Consequently, we chose to enhance DT<sub>388</sub>GMCSF specificity to AML by changing its furin cleavage region ( $_{163}\text{RVRRSV}_{170}$ ) to a uPA cleavage sequence ( $_{163}\text{GSGRSA}_{170}$ ), yielding DTU2GMCSF.

In this study, we describe the yield and the biologic properties of DTU2GMCSF. In particular, we studied the specificity, range, and potency of this new AML recombinant toxin.

From the Department of Biochemistry and Molecular Biology and Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC; Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD; and Microbial Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Submitted January 28, 2004; accepted April 5, 2004. Prepublished online as *Blood* First Edition Paper, May 25, 2004; DOI 10.1182/blood-2004-01-0339.

An Inside *Blood* analysis of this article appears in the front of this issue.

**Reprints:** Arthur E. Frankel, Hanes 4046, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157; e-mail: afrankel@wfubmc.edu.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2004 by The American Society of Hematology

## Materials and methods

### DTU2GMCSF construction

To construct the expression plasmid coding for uPA-activated DTG-MCSF, a mutagenic DNA fragment was amplified using 5' T7 promoter primer (TAATACGACTCACTATAG), 3' mutagenic primer U2 (GATTTATG**CATGACAATGAGCTACCTGCTGATCTTCCACTTCC**-ATTTCTGCACAGGCTTG; *NsiI* site is in boldface, the antisense sequence coding for uPA substrate peptide GSGRSA is underlined), and the DT<sub>388</sub>GMCSF expression plasmid pRKDTGM as a template.<sup>4</sup> The PCR product was digested with *XbaI* and *NsiI*, cloned into the *XbaI*-*NsiI* sites of pRKDTGM, yielding DTU2GMCSF expression plasmid pRKDTGM-U2.

### DTU2GMCSF expression and purification

Expression and purification of DTU2GMCSF was done according to the same strategy we used for the expression and purification of DT<sub>388</sub>GMCSF.<sup>4</sup> Briefly, pRKDTGM-U2 was used to transform BL21 (DE3) *Escherichia coli* harboring the pUBS500 plasmid. Transformants were grown in Superbroth and induced with isopropylthiogalactoside (IPTG). Inclusion bodies were isolated, washed, and denatured in guanidine hydrochloride with dithioerythritol. Recombinant protein was refolded by diluting 100-fold in cold buffer with arginine and oxidized glutathione. After dialysis, purified protein was obtained after anion-exchange, size exclusion on fast protein liquid chromatography (FPLC), and polymixin B affinity chromatography. After refolding, the production yield was 16 mg/L bacterial culture, and the purity was more than 95% as determined by Coomassie-stained sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE).

### Other toxins used

DT<sub>388</sub>GMCSF was produced in our laboratory as described previously.<sup>4</sup> DTAT consists of the translocation and catalytic domains of DT fused to the N-terminal domain of uPA, which targets DT to uPAR-expressing cells.<sup>10</sup> DTAT was a generous gift of Daniel Vallera at the University of Minnesota.

### Cells and cell lines

Human AML cell lines HL60, U937, ML1, ML2, ML17, Monomac 1, Monomac 6, CTV-1, KG-1, Sig M5, and TF1v-Src were grown as we previously described.<sup>11</sup> The 2 other human AML cell lines used in this study, TF1-vRaf and TF1-vSrc, were cultured as previously described.<sup>13</sup> Human umbilical vein endothelial cells (HUVECs) were purchased from American Type Culture Collection (Manassas, VA) and cultured according to the directions provided. Peripheral monocytes were obtained and isolated from healthy adult individuals with informed consent under a protocol approved by the Wake Forest University Institutional Review Board.<sup>14</sup>

### Cell line sensitivity to DTU2GMCSF

Aliquots of 10<sup>4</sup> cells were incubated in 100  $\mu$ L medium (same as that used to grow the cells) in Costar (Corning, NY) 96-well flat-bottomed plates in duplicate. Exogenous human pro-uPA (American Diagnostica, Stamford, CT) was added to 36 wells of each duplicate plate (100 ng/mL in each well). Then, 50  $\mu$ L DTU2GMCSF in medium was added to each column to yield concentrations ranging from 0.1 to 10 000 pM, and the cells were incubated at 37°C/5% CO<sub>2</sub> for 50 hours. Then, 1  $\mu$ Ci (0.037 MBq) <sup>3</sup>H-thymidine (NEN DuPont, Boston, MA) in 50  $\mu$ L medium was added to each well, and incubation continued for an additional 18 hours at 37°C/5% CO<sub>2</sub>. Cells were then harvested using a Skatron Cell Harvester (Skatron Instruments, Lier, Norway) onto glass fiber mats and counts per minute (cpm) of incorporated radiolabel were counted using an LKB-Wallac 1205 Betaplate liquid scintillation counter (Perkin-Elmer, Gaithersburg, MD) gated for <sup>3</sup>H. The concentration of toxin that inhibited thymidine incorporation by 50% compared to control wells (IC<sub>50</sub>). The percent maximal <sup>3</sup>H-thymidine incorporation was plotted versus the log of the toxin concentration, and nonlinear regression with a variable slope sigmoidal dose-response curve was generated

along with IC<sub>50</sub> using GraphPad Prism software (GraphPad Software, San Diego, CA). All assays were performed at least twice with an interassay range of 30% or less for IC<sub>50</sub>.

### Monocyte and HUVEC sensitivity to DTU2GMCSF

Normal cell sensitivity to DTU2GMCSF was determined using the same cytotoxicity assay described (see "Cell line sensitivity to DTU2GMCSF") with the following differences. Both normal monocytes and HUVECs were plated 24 hours prior to incubation with DTG-MCSF, DTU2GMCSF, and DTAT (only for HUVECs). Exogenous pro-uPA was not added in these assays. Cells were incubated with the toxins for 5 hours in the case of peripheral monocytes and 48 hours for HUVECs. The efficacy of DTU2GMCSF, DTG-MCSF, and DTAT on HUVECs was determined by <sup>3</sup>H-thymidine incorporation inhibition assay; 50  $\mu$ L of a 10  $\mu$ Ci (0.37 MBq)/mL <sup>3</sup>H-thymidine solution was added to each well, and the cells were harvested 24 hours after the addition of <sup>3</sup>H-thymidine. The efficacy of DTU2GMCSF and DTG-MCSF was determined by <sup>3</sup>H-leucine incorporation inhibition for normal monocytes; 100  $\mu$ L of a 20  $\mu$ Ci (0.74 MBq)/mL <sup>3</sup>H-leucine solution (NEN DuPont) was added to each well, and the cells were harvested 6 hours following the addition of <sup>3</sup>H-leucine.

### GM-CSFR expression

GM-CSFR expression levels were determined in all cell lines as described previously.<sup>15</sup> In short, aliquots of 3 to 5  $\times$  10<sup>6</sup> cells were mixed with varying amounts of <sup>125</sup>I Bolton-Hunter–labeled human GM-CSF (80–120  $\mu$ Ci [2.96–4.44 MBq]/ $\mu$ g, NEX249; NEN DuPont, Boston, MA) with or without excess (1800g [1500 ng]) cold GM-CSF (Immunex, Seattle, WA). Cells were incubated at 37°C for 1 hour and then layered over a 200  $\mu$ L oil phthalate mixture. After centrifugation at 12 000 rpm for 1 minute in a microfuge at room temperature, both pellets and supernatants were saved and counted in an LKB-Wallac 1260 multigamma counter (Turku, Finland) gated for <sup>125</sup>I with 50% counting efficiency. Background counts per minute were calculated by linear extrapolation from incubations with excess cold GM-CSF. Experiments were performed in duplicate. Receptor number/cell (B<sub>max</sub>) as well as dissociation constant (K<sub>d</sub>) were calculated using the GraphPad Prism software.

### uPAR expression

The uPAR expression levels were determined following the same protocol used for the determination of GMCSFR levels.<sup>14</sup> The amino-terminal fragment (ATF) of uPA (amino acids 1–133) was a generous gift from Dr Michael Ploug. <sup>125</sup>I labeling of the ATF was done in Iodogen-coated tubes; 8  $\mu$ g ATF was incubated with 0.5 mCi (18.5 MBq) <sup>125</sup>I and 10  $\mu$ L binding buffer for 15 minutes. The reaction was then stopped with the addition of excess amounts of binding buffer and 10  $\mu$ L of the reaction mixture was added to 900  $\mu$ L radioimmunoassay (RIA) buffer and 100  $\mu$ L tricarboxylic acid (TCA). The mixture was then centrifuged at 2000 rpm for 10 minutes, and the percentage of labeled ATF as well as the specific activity of labeled ATF was calculated by determining the amount of radioactivity in the pellet versus the amount of radioactivity in the supernatant. <sup>125</sup>I-labeled ATF was separated from free <sup>125</sup>I on a desalting column. Calculations and analysis were done using the GraphPad Prism software.

### uPA and PAI-1 levels

The uPA and plasminogen activator inhibitor 1 (PAI-1) levels were determined using enzyme-linked immunosorbent assay (ELISA) kits (American Diagnostica), and the assays were done according to the description provided in each assay kit. For each cell line 100  $\mu$ L cell culture supernatant (cell density > 106 cells/mL) was used, in duplicate, in each ELISA. Both these kits detect total levels of uPA and PAI-1.

### Blocking assays

Blocking assays were performed to test the ability of specific anti-GM-CSF and anti-uPA antibodies to block the killing of the sensitive cell lines by DTU2GMCSF. The same thymidine incorporation inhibition assays were

**Table 1. AML cell line sensitivity to DTU2GMCSF, DTU2GMCSF plus pro-uPA, and DT<sub>388</sub>GMCSF as determined by <sup>3</sup>H-thymidine incorporation inhibition assays**

Cell line	DTU2GMCSF, IC <sub>50</sub> , pM	DTU2GMCSF + pro-uPA, IC <sub>50</sub> , pM	DT <sub>388</sub> GMCSF, IC <sub>50</sub> , pM
U937	34.7	0.48	0.47
TF1-vRaf	3.14	0.26	0.64
KG-1	9.8	3.5	2.5
HL60	7.8	1.5	2.7
ML2	5.8	0.76	1.9
TF1-vSrc	> 4000	0.55	0.84
TF1-HaRas	> 4000	0.67	0.27
Sig M5	> 4000	42	21.1
ML1	> 4000	30	22
ML17	> 4000	4.5	3.1
Monomac 6	> 4000	1730	68.3
Monomac 1	> 4000	> 4000	3.2
CTV-1	> 4000	> 4000	> 4000

performed as described (see "Cell line sensitivity to DTU2GMCSF") but without the addition of pro-uPA. In the blocking assays, 10 μg/mL monoclonal anti-uPA antibody (American Diagnostica) or 2 μg/mL monoclonal anti-GM-CSF antibody (Oncogene Research, San Diego, CA) was added to the cells 2 hours before the addition of DTU2GMCSF. The rest of the assay proceeded as described.

## Results

### DTU2GMCSF expression and purification

Recombinant protein was expressed in *E coli*, purified from inclusion bodies with a yield of 16 mg/L bacterial culture and a purity of more than 95% by Coomassie-stained SDS-PAGE. DTU2GMCSF is refolded as described previously for the refolding of DT<sub>388</sub>GMCSF.<sup>4</sup> The percent of properly folded protein recovered from the inclusion bodies is about 25%.

### DTU2GMCSF cytotoxicity


To determine the biologic activity of DTU2GMCSF, we tested the cytotoxicity of this fusion protein on a panel of 13 AML cell lines (Table 1). Tritiated thymidine incorporation inhibition assays were done using DTU2GMCSF with or without the addition of exogenous pro-uPA as well as using DT<sub>388</sub>GMCSF. All cell lines tested had a high sensitivity to DT<sub>388</sub>GMCSF except CTV-1, which had an IC<sub>50</sub> for DT<sub>388</sub>GMCSF more than 4000 pM. This cell line was also not sensitive to DTU2GMCSF with or without the addition of exogenous pro-uPA. Five of 13 cell lines, namely, U937, TF1-vRaf, KG-1, HL60, and ML2, were highly sensitive to DTU2GMCSF without the addition of exogenous pro-uPA (IC<sub>50</sub> = 3.14-34.7 pM; Table 1; Figure 1A). When these cells were coincubated with DTU2GMCSF and exogenous pro-uPA, the cytotoxicity of DTU2GMCSF significantly increased and became similar to that of DT<sub>388</sub>GMCSF (IC<sub>50</sub> = 2.6-3.5 pM). Another 5 of 13 cell lines, namely, TF1-vSrc, TF1-HaRas, Sig M5, ML1, and ML17, were not sensitive to DTU2GMCSF. These cell lines, however, when coincubated with both DTU2GMCSF and exogenous pro-uPA had significantly increased sensitivity to DTU2GMCSF (IC<sub>50</sub> = 0.55-42 pM), becoming similar to the sensitivity of these cells to DT<sub>388</sub>GMCSF (Table 1; Figure 1B). The remaining 3 cell lines, Monomac 1, Monomac 6, and CTV-1, were not sensitive to DTU2GMCSF even when exogenous pro-uPA was added. Monomac 1 and Monomac 6 were sensitive to DT<sub>388</sub>GMCSF (IC<sub>50</sub> = 3.2 and 68.3 pM, respectively), whereas CTV-1 was not sensitive even to DT<sub>388</sub>GMCSF (Table 1; Figure 1C).

### Inhibition assays


To show the absolute requirement for the presence of GM-CSFR and an active uPA/uPAR protease system for DTU2GMCSF toxicity, we inhibited each of these components separately and looked at the effects of these inhibitions on the efficiency of DTU2GMCSF. We inhibited the uPA/uPAR system by preincubating TF1-vRaf cells with a specific monoclonal antibody directed

**Figure 1. Proliferation inhibition assays on 3 AML cell lines.**

Results of inhibition assays are shown for TF1-vRaf (A), ML1 (B), and Monomac 6 (C) using DT<sub>388</sub>GMCSF (▲), DTU2GMCSF (▼), and DTU2GMCSF plus exogenous pro-uPA (■). The x-axis represents the log of the molar drug concentration and the y-axis represents cell viability expressed as percent control of <sup>3</sup>H-thymidine incorporation in counts per minute. TF1-vRaf was sensitive to DTU2GMCSF (IC<sub>50</sub> = 3.14 pM); the sensitivity was enhanced by the addition of exogenous pro-uPA (IC<sub>50</sub> = 0.26 pM) and became similar to that of DT<sub>388</sub>GMCSF (IC<sub>50</sub> = 0.64 pM) (A). ML1 was not sensitive to DTU2GMCSF unless exogenous pro-uPA was added (IC<sub>50</sub> = 30 pM). The IC<sub>50</sub> for DT<sub>388</sub>GMCSF was 22 pM (B). Monomac 6 was not sensitive to DTU2GMCSF even when exogenous pro-uPA was added (C). (D) Blocking assay. The proliferation inhibition assay on TF1-vRaf with DTU2GMCSF (▲), DTU2GMCSF plus anti-uPA (■), and DTU2GMCSF plus anti-GM-CSF (▼) is shown. On the x-axis is the log molar drug concentration, on the y-axis is the percentage of control <sup>3</sup>H-thymidine incorporation. Both anti-GM-CSF and anti-uPA greatly decreased DTU2GMCSF efficacy (IC<sub>50</sub> = 400 pM and 0.67 μM, respectively) compared to an IC<sub>50</sub> = 2.3 pM for DTU2GMCSF alone, thus demonstrating the dual specificity of DTU2GMCSF, which requires the expression of both GM-CSFR and the uPA/uPAR protease system.







**Figure 2.** uPAR levels as determined by  $^{125}\text{I}$ -ATF receptor-binding assay. (A) HL60 GM-CSFR levels were determined by  $^{125}\text{I}$ -GM-CSF receptor-binding assay. (B) uPAR expression levels of Sig M5. The x-axis represents the concentration of  $^{125}\text{I}$ -ATF (pg/mL); the y-axis represents the amount of cell-bound  $^{125}\text{I}$ -ATF (cpm). (C) uPAR levels expressed as number of receptors/cell in the 13 AML cell lines. DTU2GMCSF-resistant cells (black) have lower uPAR expression levels than DTU2GMCSF-sensitive cells (white, without the addition of pro-uPA; gray, requiring the addition of pro-uPA).

against an epitope close to the active site of double-chain uPA. This antibody binds and inactivates all forms of uPA (single-chain pro-uPA and double-chain uPA), and it inhibits the proteolytic activity of active double-chain uPA even in its uPAR-bound form. Incubation of the cells with 10  $\mu\text{g}/\text{mL}$  anti-uPA antibody increased the  $\text{IC}_{50}$  of DTU2GMCSF by 106-fold ( $\text{IC}_{50} = 0.62 \mu\text{M}$ ) as compared to DTU2GMCSF alone ( $\text{IC}_{50} = 16.6 \text{ pM}$ ; Figure 1D). We separately inhibited the binding of DTU2GMCSF to its GM-CSFR by cotreating cells with an anti-GM-CSF monoclonal antibody that targets an epitope near the GM-CSFR-binding site on GM-CSF and subsequently blocks binding of GM-CSF to its receptor. Incubation of the cells with 2  $\mu\text{g}/\text{mL}$  anti-GM-CSF increased the  $\text{IC}_{50}$  of DTU2GMCSF by 200-fold ( $\text{IC}_{50} = 400 \text{ pM}$ ) as compared to the  $\text{IC}_{50}$  of DTU2GMCSF alone (2.3 pM; Figure 1D).

### Receptor levels

To determine the minimal expression levels of GM-CSFR and uPAR needed for DTU2GMCSF to be active, we determined the expression levels of these 2 receptors in the 13 AML cell lines tested for cytotoxicity and correlated these expression levels to the sensitivity of each cell line for DTU2GMCSF. GM-CSFR levels varied between 108 receptors/cell for CTV-1 and 11 430 receptors/cell for TF1-HaRas (Figure 2A). The low GM-CSFR-expressing CTV-1 cells were resistant to both DT<sub>388</sub>GMCSF and DTU2GMCSF. GM-CSFR density correlated with the sensitivity of each cell line to DT<sub>388</sub>GMCSF (Table 2). Among the 12 cell lines that were sensitive to DT<sub>388</sub>GMCSF, Sig M5 had the lowest number

**Table 2.** Comparison of DT<sub>388</sub>GMCSF efficacy ( $\text{IC}_{50}$ ) and GMCSFR expression levels

Cell line	GMCSFR levels, receptors/cell	DT <sub>388</sub> GMCSF, $\text{IC}_{50}$ , pM
TF1-HaRas	11 430	0.27
U937	2 329	0.47
TF1-vRaf	7 624	0.64
TF1-vSrc	5 846	0.84
ML2	1 209	1.9
KG-1	869	2.5
HL60	3 262	2.7
ML17	456	3.1
Monomac 1	304	3.2
Sig M5	236	21
ML-1	358	22
Monomac 6	712	68.3
CTV-1	108	> 4000


of GM-CSFRs (236 receptors/cell). Therefore, the minimum number of GM-CSFRs required for a cell to be sensitive to DT<sub>388</sub>GMCSF in our survey was 236 receptors/cell. The 2 cell lines that were sensitive to DT<sub>388</sub>GMCSF but not sensitive to DTU2GMCSF had very low levels of uPAR expression. uPAR levels in these cell lines were 33 receptors/cell for Monomac 1 and 45 receptors/cell for Monomac 6. On the other hand, the 10 cell lines that were sensitive to DTU2GMCSF with or without the addition of pro-uPA had high levels of uPAR expression. uPAR levels varied between 387 and 1848 receptors/cell for the 5 cell lines that were sensitive to DTU2GMCSF alone (Table 3). Receptor levels varied between 54 and 991 receptors/cell for the 5 cell lines that were sensitive to DTU2GMCSF only when pro-uPA was added (Figure 2B-C; Table 3). The sensitive cell line with the lowest uPAR expression levels (ML17) had 54 receptors/cell and was sensitive to DTU2GMCSF when excess uPA was added. Therefore, the minimum expression levels of uPAR required for the cells to be sensitive to DTU2GMCSF in our survey was 54 receptors/cell. uPAR expression levels in the DTU2GMCSF-resistant cell lines were significantly lower than expression levels in all other cell lines. On the other hand, uPAR expression levels in cell lines sensitive to DTU2GMCSF did not distinguish cell lines requiring the addition of exogenous pro-uPA from those not requiring exogenous pro-uPA

**Table 3.** uPAR expression levels, total uPA levels, and DTU2GMCSF efficacy, with or without pro-uPA, on the 12 AML cell lines that were sensitive to DT<sub>388</sub>GMCSF

Cell line	uPAR levels, no. receptors/cell	Total uPA levels, ng/mL	DTU2GMCSF, $\text{IC}_{50}$ , pM	DTU2GMCSF + pro-uPA, $\text{IC}_{50}$ , pM
TF1-vRaf	1848	0.116	3.14	0.26
ML2	784	0.283	5.8	0.76
U937	480	0.135	34.7	0.48
KG-1	399	0.326	9.8	3.5
HL60	387	0.489	7.8	1.5
ML1	991	0.094	> 4000	30
TF1-HaRas	581	0.092	> 4000	0.67
TF1-vSrc	491	0.054	> 4000	0.55
Sig M5	241	0.090	> 4000	42
ML17	54	0.294	> 4000	4.5
Monomac 6	45	0.559	> 4000	1730
Monomac 1	33	0.931	> 4000	> 4000
CTV-1*	110	0.32	> 4000	> 4000

\*This cell line was not sensitive to DT<sub>388</sub>GMCSF because of low GM-CSFR expression levels and was not included in the correlation of DTU2GMCSF efficacy with uPAR expression levels and total uPA levels.

**Figure 3. uPA and PAI-1 levels.** (A) Average uPA levels (ng/mL) in the supernatant of each of the 3 categories of AML cell lines as determined by ELISA are shown. Nonsensitive cell lines (black) had the highest concentrations of total uPA in their supernatants, which indicates that DTU2GMCSF efficacy is determined by uPAR expression levels rather than uPA concentration. Cell lines that were sensitive to DTU2GMCSF only when exogenous pro-uPA was added (gray) had significantly lower total uPA levels in their supernatants as compared to cells that did not require the addition of exogenous pro-uPA (white;  $P = .04$ ). (B) Total PAI-1 concentrations in the supernatants of the AML cell lines as determined by ELISA are shown. PAI-1 levels did not correlate with DTU2GMCSF efficacy.



**uPA and PAI-1 levels**

We determined total uPA levels in cultures with densities comprised between 1.5 and 2 million cells/mL, using an ELISA kit that detects all forms of uPA, that is, inactive single-chain pro-uPA as well as double-chain active uPA. Total uPA levels in the 13 cell lines tested varied between 0.1 and 0.93 ng/mL (Table 3). The highest levels of total uPA were observed in the cell lines that are resistant to DTU2GMCSF; these levels were 0.93 ng/mL for Monomac 1, 0.55 ng/mL for Monomac 6, and 0.32 ng/mL for CTV-1. We do not have any explanation for why the 3 cell lines that were not sensitive to DTU2GMCSF had the highest total uPA levels. However, this result indicates that in the absence of adequate uPAR expression, cells were resistant to DTU2GMCSF even in the presence of relatively high levels of total uPA. Further, cells that were sensitive to DTU2GMCSF without the addition of pro-uPA had significantly higher total uPA levels than cell lines that needed the addition of exogenous pro-uPA to be sensitive (Figure 3A). PAI-1 levels varied between 0.018 and 0.903 ng/mL and did not correlate with the sensitivity of each cell line to DTU2GMCSF. Three cell lines, namely, HL60, Sig M5, and Monomac 1, did not have any detectable levels of PAI-1 (Figure 3B). However, this finding does not rule out the possibility of PAI-1 activity being a major regulator of DTU2GMCSF efficacy in vivo. Therefore, we were unable in this study to determine the role played by PAI-1 in the efficacy of DTU2GMCSF.

**DTU2GMCSF toxicity to normal cells**

To determine the toxicity of DTU2GMCSF to normal cells we tested the sensitivity of both peripheral monocytes and HUVECs to DTU2GMCSF and DTGMCSF. Normal peripheral monocytes, with GM-CSFR but low uPA/uPAR protease activity, were 103-fold less sensitive to DTU2GMCSF than to DT<sub>388</sub>GMCSF. HUVECs, cells that express uPAR but low or absent GM-CSFR, were resistant to both DTGMCSF and DTU2GMCSF but sensitive to DTAT ( $IC_{50} = 26.8$  pM). Thus, DTU2GMCSF is a dual-specificity cytotoxin requiring the presence of GM-CSFR and an active uPA/uPAR protease system (Table 4).

**Table 4. DTU2GMCSF toxicity on normal cells**

Cell type	DTU2GMCSF, $IC_{50}$ , pM	DT <sub>388</sub> GMCSF, $IC_{50}$ , pM	DTAT, $IC_{50}$ , pM
HUVECs	> 4000	> 4000	26.8
Human monocytes	124	0.16	—

— indicates not tested.

**Discussion**

Our laboratory has focused on the development of DT fusion toxins for therapy of chemotherapy-resistant AML. The first generation of DT fusion toxins for AML have only a single targeting moiety—the ligand. Thus, our first AML fusion toxins (DT<sub>388</sub>GMCSF, DT<sub>388</sub>IL3, and DTAT) were potentially toxic to normal tissues bearing their respective receptors—GM-CSFR, interleukin 3 receptor (IL-3R), or uPAR.<sup>4,12,16</sup> Clinical testing of the first AML fusion toxin DT<sub>388</sub>GMCSF confirmed clinical efficacy but with associated damage to GM-CSFR-containing normal cells. This led to significant liver injury. We chose to re-engineer fusion toxins to enhance specificity and reduce normal tissue toxicity. Based on the studies of Liu and colleagues<sup>9</sup> with anthrax protective antigen, we reasoned that the AML specificity of DT<sub>388</sub>GMCSF could be increased by modifying the DT furin site to require an active AML-selective protease system. We and others have shown uPA and uPAR in patient AML blasts.<sup>12,17</sup> Thus, we reasoned that by replacing DT<sub>163</sub>RVRRSV<sub>170</sub> with the uPA cleavage sequence<sub>163</sub>GSGRSA<sub>170</sub> in DT<sub>388</sub>GMCSF, the new AML fusion toxin DTU2GMCSF would retain potency but have enhanced AML specificity. The new dual-specificity fusion toxin DTU2GMCSF was produced in the same yields and purity as DT<sub>388</sub>GMCSF. The protein remained stable and biologically active after storage at  $-80^{\circ}C$  for over 1 month (R.J.A.-H. and A.F., unpublished observations, February 2003). Further, DTU2GMCSF remained fairly stable after incubation with serum at  $37^{\circ}C$  for 48 hours ( $IC_{50} = 12.8$  pM as compared to an  $IC_{50} = 6.3$  pM for freshly thawed DTU2GMCSF in a tritiated thymidine incorporation inhibition assay on HL60 cells; data not shown).

Remarkably, DTU2GMCSF showed potency similar to DT<sub>388</sub>GMCSF when exogenous single-chain pro-uPA was added. This suggests that uPAR is expressed in adequate levels on most AML cell lines. The deficiency of uPA, in some cases, may be an artifact of in vitro culture or may occur during cell line generation. In vivo, there may be higher concentrations of uPA in the tumor environment.<sup>18</sup> Even without exogenous pro-uPA, 5 (39%) of 13 cell lines were killed by DTU2GMCSF. Thus, a significant fraction of patients may have disease sensitive to this fusion toxin.

DTU2GMCSF is a dual-specificity fusion toxin. Blocking assays, normal tissue toxicities, and cell line receptor studies show that both uPA/uPAR and GM-CSFR are required for DTU2GMCSF toxicity. Several groups have made toxins targeting more than one tumor cell receptor.<sup>19,20</sup> In most cases, the toxins had 2 ligands and thus were able to intoxicate cells with either ligand, for example, IL-13R and uPAR,<sup>19</sup> and epidermal growth factor (EGF) receptor and erbB-2.<sup>20</sup> Hence, although the new molecules were able to bind

a larger range of tumor cells, they had less rather than more specificity.

We provide a proof of principle for the efficacy and increased specificity of dual-specificity fusion toxins. Further studies are needed to determine the *in vivo* efficacy and safety of DTU2GMCSF. Hopefully, this dual-specificity AML fusion toxin

will be clinically beneficial to patients with chemotherapy-refractory AML. Similar approaches with other fusion toxins may provide opportunities to treat metastatic solid tumors. Many of the receptor targets for fusion toxins have limited specificity; hence, addition of a requisite toxin-processing step with tumor-selective proteases may yield safer active fusion toxins for cancer treatment.

## References

- Bennett JM, Kouides PA, Forman SJ. The myelodysplastic syndromes: morphology, risk assessment, and clinical management. *Int J Hematol*. 2002;76(suppl 2):228-238.
- Choe S, Bennett MJ, Fujii G, et al. The crystal structure of diphtheria toxin. *Nature*. 1992;357:216-222.
- VanderSpek JC, Murphy JR. Fusion protein toxins based on diphtheria toxin: selective targeting of growth factor receptor of eukaryotic cells. *Methods Enzymol*. 2000;327:239-249.
- Frankel AE, Ramage J, Latimer A, et al. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for phase I clinical trials. *Protein Expr Purif*. 1999;16:190-201.
- Perentesis JP, Bendel AE, Shao Y, et al. Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias. *Leuk Lymphoma*. 1997;25:247-256.
- Hogge DE, Willman CL, Kreitman RJ, et al. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. *Blood*. 1998;92:589-595.
- Hall PD, Willingham MC, Kreitman RJ, Frankel AE. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. *Leukemia*. 1999;13:629-633.
- Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. *Clin Cancer Res*. 2002;8:1004-1013.
- Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. *J Biol Chem*. 2001;276:17976-17984.
- Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. *Cell Mol Life Sci*. 2000;57:25-40.
- Dano K, Romer J, Nielsen BS, et al. Cancer invasion and tissue remodeling—cooperation of protease systems and cell types. *APMIS*. 1999;107:120-127.
- Ramage J, Valleria DA, Black JH, Aplan PD, Kees UR, Frankel AE. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. *Leuk Res*. 2003;27:79-84.
- Kiser M, McCubrey JA, Steelman LS, et al. Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice. *Leukemia*. 2001;15:814-818.
- Boyum A. Separation of white blood cells. *Nature*. 1964;204:793-794.
- Frankel AE, Lilly M, Kreitman R, et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. *Blood*. 1998;92:4279-4286.
- Urieto JO, Liu T, Black JH, et al. Expression and purification of the recombinant diphtheria toxin DT388IL3 for phase I clinical trials. *Protein Expr Purif*. 2004;33:123-133.
- Jardi M, Ingles-Esteve J, Burgal M, et al. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells. *Thromb Haemost*. 1996;76:1009-1019.
- Tapiovaara H, Alitalo R, Stephens RW, Myohanen H, Ruutu T, Vaheri A. Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients. *Blood*. 1993;82:914-919.
- Todhunter DA, Hall WA, Rastamzadeh E, Shu Y, Doumbia SO, Valleria DA. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model of glioblastoma. *Protein Engineering Design and Selection*. 2004;17:157-164.
- Schmidt M, Hynes NF, Groner B, Wels W. A bivalent single chain antibody-toxin specific for erbB-2 and the EGF receptor. *Int J Cancer*. 1996;65:538-546.